Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO group

This publication has 15 references indexed in Scilit:

• Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
  New England Journal of Medicine, 2025
• Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper
  Critical Reviews in Oncology/Hematology, 2024
• Management of infusion-related reactions in cancer therapy: strategies and challenges
  ESMO Open, 2024
• Metastatic colorectal cancer: mechanisms and emerging therapeutics
  Trends in Pharmacological Sciences, 2023
• Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) – A case series
  European Journal of Cancer, 2022
• Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies
  European Journal of Cancer, 2022
• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
  New England Journal of Medicine, 2019
• Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2018
• Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
  The Lancet Oncology, 2014
• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
  Nature, 2012